2016
Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rateComparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group†
Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, Guerrera F, Venuta F, van Raemdonck D, Travis W, Lucchi M, Rimner A, Thomas P, Weder W, Rocco G, Detterbeck F, Korst R. Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group†. European Journal Of Cardio-Thoracic Surgery 2016, 50: 766-771. PMID: 27032473, PMCID: PMC6279171, DOI: 10.1093/ejcts/ezw107.Peer-Reviewed Original ResearchConceptsNeuroendocrine thymic tumoursRecurrence-free survivalThymic carcinomaOverall survivalSurvival rateThymic tumorsThoracic surgeonsFive-year recurrence-free survivalWorld Health Organization histological classificationRetrospective multicentre cohort studyInternational Thymic Malignancy Interest GroupMedian overall survivalMulticentre cohort studyEuropean SocietyKaplan-Meier methodThymic epithelial tumorsLarge clinical seriesLog-rank testComparison of outcomesGroup of tumorsR0 resectionCohort studyPrognostic factorsNET patientsTC patients
2015
What is quality, and can we define it in lung cancer?—the case for quality improvement
Farjah F, Detterbeck FC. What is quality, and can we define it in lung cancer?—the case for quality improvement. Translational Lung Cancer Research 2015, 4: 365-72. PMID: 26380177, PMCID: PMC4549465, DOI: 10.3978/j.issn.2218-6751.2015.07.12.Peer-Reviewed Original Research